Semax vs Selank: Comparing Two Nootropic Peptides

Semax and Selank are two of the most frequently compared synthetic peptides in the nootropic research literature, and for understandable reasons: both are short heptapeptides developed in Russia at the Institute of Molecular Genetics of the Russian Academy of Sciences, both are administered intranasally in study protocols, and both carry an identical Pro-Gly-Pro tail that protects them from rapid enzymatic breakdown. Researchers searching for this comparison are usually trying to distinguish a peptide studied mainly for cognition and neuroprotection from one studied mainly for anxiety and stress.

This article contrasts Semax and Selank across structure, mechanism, evidence base, and research focus. Despite their surface similarities, the two peptides descend from entirely different parent molecules and are investigated for largely non-overlapping purposes.

Research-only notice: Semax and Selank are experimental compounds intended for laboratory and preclinical research. Neither is approved for human use outside the Russian Federation and a small number of neighbouring countries. Nothing here is medical advice, a dosing recommendation, or a claim of safety or efficacy in humans.

Mechanism of action

Semax is built on the 4-10 fragment of adrenocorticotropic hormone (ACTH), a melanocortin sequence. The added Pro-Gly-Pro extension is reported to remove the hormone’s steroidogenic (cortisol-releasing) activity while stabilising the molecule, leaving a peptide studied for neurotrophic effects. Its best-characterised action is rapid up-regulation of brain-derived neurotrophic factor (BDNF) and its receptor TrkB, together with nerve growth factor (NGF), in the hippocampus and cortex. A single dose has been reported to raise BDNF protein and mRNA in different areas of the rat brain within hours (Dolotov et al., 2003), engaging downstream MAPK/ERK and PI3K/Akt survival cascades. Semax also modulates dopaminergic and serotonergic signalling, which is thought to contribute to its reported effects on attention and arousal.

Selank derives from tuftsin (Thr-Lys-Pro-Arg), a naturally occurring immunomodulatory fragment of the IgG heavy chain, again carrying a Pro-Gly-Pro extension. Its most discussed mechanism is inhibition of the enzymes that degrade enkephalins, thereby raising endogenous opioid-peptide tone. It is also reported to modulate the GABAergic system and the balance of monoamines, and to shift the expression of stress- and anxiety-related genes. In a neuroblastoma cell-culture study, Selank alone did not change GABAergic gene expression but altered the cellular response to GABA and to olanzapine (Filatova et al., 2017), consistent with a modulatory rather than a direct-agonist role.

A notable point of overlap: both peptides inhibit the enkephalin-degrading enzymes of human serum, with Semax and Selank showing IC50 values in the low-micromolar range (roughly 10 and 20 micromolar, respectively) in the same study (Kost et al., 2001). This shared biochemistry helps explain why two structurally different peptides can produce partly overlapping neuromodulatory effects.

Evidence and development status

Both compounds are unusual among nootropic peptides in having genuine human clinical data, but that data comes almost entirely from Russian research groups and is not widely replicated in independent Western trials. Semax has been registered as a drug in Russia since 1994 and appears on the country’s list of vital and essential medicines; its strongest clinical claims are in acute ischaemic stroke and in cognitive and attention disorders, supported by trials reporting shifts toward anti-inflammatory mediators and improved neurological scores. Selank has been evaluated in controlled trials for generalized anxiety disorder and neurasthenia, where investigators described anxiolytic activity comparable to the benzodiazepine medazepam but without the associated sedation, alongside antiasthenic effects (Zozulia et al., 2008).

For both peptides the evidence should be read with caution. Sample sizes are often modest, methods and outcome scales are not always transparent to non-Russian readers, and independent replication is limited. They are best described as clinically used in one jurisdiction but experimental everywhere else.

Research context

The practical distinction researchers draw is one of emphasis. Semax is studied where the question is neurotrophic support, neuroprotection, and cognition, in stroke and hypoxia models and in learning and attention paradigms. Selank is studied where the question is anxiety, stress reactivity, and the interface between the nervous and immune systems, reflecting its tuftsin ancestry. Their shared Pro-Gly-Pro motif, short plasma residence, intranasal delivery, and enkephalinase inhibition mean they are often grouped together, yet the behavioural literature keeps them in separate lanes.

Key differences

• Parent molecule: Semax derives from the ACTH/melanocortin fragment; Selank derives from the immunopeptide tuftsin.
• Primary read-out: Semax is characterised chiefly by BDNF/NGF up-regulation and neuroprotection; Selank chiefly by anxiolytic, enkephalin-sparing and immunomodulatory effects.
• Lead indication studied: ischaemic stroke and cognition for Semax; generalized anxiety and asthenia for Selank.
• Neurotransmitter emphasis: Semax leans dopaminergic, serotonergic and neurotrophic; Selank leans GABAergic and enkephalinergic.
• Shared trait: both are Russian intranasal heptapeptides that inhibit serum enkephalin-degrading enzymes and can raise BDNF.

Which for what research?

Framed strictly as a research decision, Semax is the more relevant tool where the experimental question concerns neurotrophic signalling, neuroprotection, ischaemia, or cognition and attention, given its ACTH-derived, BDNF-centred profile and its clinical footprint in stroke. Selank is the more relevant tool where the question concerns anxiety-like behaviour, stress resilience, or neuro-immune interactions, reflecting its tuftsin lineage and enkephalin-sparing mechanism. Because their mechanisms partially overlap through shared enkephalinase inhibition and BDNF effects, some study designs examine them side by side rather than as substitutes. Neither is a validated human therapeutic outside Russia, and any research use should be governed by the applicable ethical and legal framework rather than by extrapolation from the other compound. Put these side by side in the Compare Peptides tool.

Sources

• Dolotov OV, et al. The heptapeptide SEMAX stimulates BDNF expression in different areas of the rat brain in vivo. Neurosci. PMID 14556513
• Binding of Semax (ACTH 4-10 heptapeptide) to plasma membranes of the rat forebrain basal nuclei and its biodegradation. PMID 15344653
• Kost NV, Sokolov OY, et al. Semax and Selank inhibit the enkephalin-degrading enzymes from human serum. Russ J Bioorg Chem, 2001. PMID 11443939
• Zozulia AA, Neznamov GG, et al. Efficacy and possible mechanisms of action of the peptide anxiolytic Selank in generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr, 2008. PMID 18454096
• Filatova E, et al. GABA, Selank, and Olanzapine affect the expression of genes involved in GABAergic neurotransmission in IMR-32 cells. Front Pharmacol, 2017. PMID 28293190